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Abstract
Background: The specificity of a nuclear receptor's ability to modulate gene expression resides
in its ability to bind a specific lipophilic ligand, associate with specific dimerization partners and bind
specific DNA sequences in the promoter regions of genes. This sequence of events appears to be
the basis for targeting an additional regulatory complex composed of a variety of protein and RNA
components that deliver signals for facilitation or inhibition of the RNA polymerase complex.
Characterization of the tissue and cell-specific components of these coregulatory complexes
appear to be integral to our understanding of nuclear receptor regulation of transcription.
Results: A novel yeast screen sensitive to retinoid-X receptor (RXR) transcriptional activation
resulted in the isolation of the rat homologue of the mouse NPDC-1 gene. NPDC-1 has been
shown to be involved in the control of neural cell proliferation and differentiation, possibly through
interactions with the cell cycle promoting transcription factor E2F-1. Although the amino acid
sequence of NPDC-1 is highly conserved between mouse, rat and human homologues, their tissue
specific expression was seen to vary. A potential for direct protein:protein interaction between
NPDC-1, RXR and retinoic acid receptor beta (RARβ) was observed in vitro and NPDC-1
facilitated RXR homodimer and RAR-RXR heterodimer DNA binding in vitro. Expression of
NPDC-1 was also observed to repress transcription mediated by retinoid receptors as well as by
several other nuclear receptor family members, although not in a universal manner.
Conclusions: These results suggest that NPDC-1, through direct interaction with retinoid
receptors, functions to enhance the transcription complex formation and DNA binding function of
retinoid receptors, but ultimately repress retinoid receptor-mediated gene expression. As with
NPDC-1, retinoids and their receptors have been implicated in brain development and these data
provide a point of convergence for NPDC-1 and retinoid mediation of neuronal differentiation.

Background
Retinoids are a class of compounds that demonstrate a
profound effect on cellular differentiation and proliferation [1–4]. The physiologically active retinoid metabolite,

all-trans retinoic acid (atRA) regulates gene expression by
complexing with members of the steroid/hormone family
of nuclear receptors. Two groups of nuclear receptors have
been shown to mediate retinoid signaling. The three
Page 1 of 19
(page number not for citation purposes)

Nuclear Receptor 2003, 1

isotypes (α, β and γ) of retinoic acid receptor (RAR) bind
atRA in acquiring a transcriptionally active state [3,5,6]. A
second group of receptors, called the retinoid-X receptors
(RXRs; isotypes α, β and γ), bind to an atRA isomer, 9-cis
retinoic acid (9cRA), and can activate transcription as a
homodimer complex [6–8]. However, the predominant
physiological function of RXRs may be as an obligate heterodimer partner for a number of other nuclear receptors
including the thyroid hormone receptors, the peroxisome
proliferator activated receptors, the vitamin D receptor as
well as the RARs [9–11].
Steroid/hormone nuclear receptors regulate the expression of specific target genes by binding to cis-acting DNA
sequences called hormone response elements (HREs).
RAR/RXR heterodimers preferentially bind HREs categorized as direct repeats of the half-site consensus sequence
AGGTCA or AGTTCA separated by five or two nucleotides,
referred to as a DR5 and DR2 respectively. One of the first
and most potent RAR HRE identified was the DR5 motif
in the promoter of the RARβ gene itself [12].
Retinoid induced transcriptional activation in mammalian cells is influenced by the cell cycle regulator E2F-1
[13]. The E2F-1 transcription factor is part of a multi-protein family that regulates the expression of gene products
needed for the initiation and completion of DNA synthesis [14,15]. E2F-1 and other members of this family share
the ability to induce the transition from G1 to S phase of
the cell cycle. E2F dependent transcription is thought to
be dominantly regulated by interactions with the retinoblastoma (Rb) gene product and other Rb-related proteins
(reviewed in [16]). It has been demonstrated that coexpression of E2F-1 inhibits atRA induced transcription
from a RARβ response element driven reporter plasmid
[13]. However, the E2F-1 protein could not be demonstrated to directly bind to the RARs or the βRE, suggesting
an interaction with a common accessory factor or factors.
The mechanism of steroid/hormone nuclear receptor
function includes interaction with a number of recently
identified co-regulators [17–21]. The yeast two-hybrid
system and far-western blotting have been used to identify
several proteins that associate with nuclear receptors in a
ligand-dependent manner. These include the co-repressors SMRT and N-CoR, the coactivators SRC-1 and RIP140 and the integrator proteins p300 and CBP. Recently,
a short conserved amino acid sequence motif (LXXLL) has
been reported to be necessary and sufficient to mediate
the binding of RIP-140, SRC-1 and CBP to liganded
nuclear receptors [22,23]. For the most part, these co-regulators have not been shown to be specifically expressed
with respect to receptor function and usually demonstrate
a significant degree of interaction overlap between various
nuclear receptors. RXRs are promiscuous in association
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with multiple nuclear receptors and therefore would be an
excellent target by which co-regulator function could
effect sweeping changes in transcriptional regulation associated with complex cellular processes such as
differentiation.
We and others have shown that it is possible to reconstitute RXR transcriptional function in yeast [24–26]. In this
study, we attempted to identify, from randomly expressed
rat cDNA sequences, proteins that positively influence
RXR mediated transcription in yeast. A cDNA sequence
was isolated containing an open reading frame (ORF)
which coded for a protein that has a very high amino acid
identity (94%) with a previously described mouse neural
proliferation, differentiation and control protein (NPDC1) [27]. More recently, a human isoform has been identified sharing similar structural feature but differing in its
tissue distribution [28]. Mouse NPDC-1 expression has
been demonstrated to down-regulate cell proliferation in
a reversible fashion and suppress transformation properties when stably transfected into cell lines [27]. A proteinprotein interaction has also been shown between mouse
NPDC-1 and the cell cycle regulator E2F-1 [29,30]. Alignment of the mouse, rat and human NPDC-1 proteins
reveals a conserved LXXLL amino acid sequence proximal
to their amino terminus. In this paper we demonstrate
that NPDC-1 can physically interact with RXR and RAR,
and can repress retinoid signaling in a mammalian cell
transcription assay. We also show that NPDC-1 can
repress transcription events mediated by retinoid receptors and several other steroid/nuclear receptor family
members, can modulate binding of retinoid receptors to
their response elements and can inhibit the endogenous
activity of an E2F transcriptional reporter plasmid in
mammalian cells. Together with previously published
information, these data support a hypothetical role for
NPDC-1 in neuronal proliferation and differentiation as a
corepressor of retinoid receptor and E2F-1 mediated gene
transcription events.

Results
Functional Yeast Screen Identifies a RXR Transcription Coregulator
RXR transcriptional activation was reconstituted in yeast
by manipulation of the S. cerevisiae auxotrophic mutant
cell line BJ5409. Yeast transcription reporter plasmids
incorporate a HRE into an enhancerless gal 1 promoter
controlling the conditional expression of a βGal gene. A
RXR expressing, βRE-βGal reporter plasmid yeast transformant was isolated and maintained by nutritional selection. Confirmation of the maintenance of both plasmids
was demonstrated by ligand (9cRA) dose dependent
induction of βGal expression (Fig. 1A). A third nutritionally selectable plasmid expressing a rat brain cDNA library
(pcRB) [31] was then transformed into these yeast and
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Figure
Rat
brain1 cDNA expression library screening in yeast identifies a plasmid containing an approximately 1
Rat brain cDNA expression library screening in yeast identifies a plasmid containing an approximately 1.4 kb
cDNA fragment capable of enhancing RXR transcriptional activation. (A) Yeast cells transformed with the β-galactosidase reporter vector YRpβRE and the yeast expression vector YEpRXRα were exposed to increasing concentrations of 9cis retinoic acid (9cRA). The βGal activity present in yeast extracts was measured as the colorimetric change of the βGal substrate ONPG (A415) normalized for cell number approximations (A600). The dose response of YRpβRE transformed yeast is
also shown (Reporter Alone). Values reported are averages of duplicate data points. (B) An outline of the screening strategy
used to identify a RXR transcriptional enhancing cDNA product. Transformed yeast expressing rat brain cDNA products that
elevate transcription of the βGal reporter gene result in the formation of blue colonies. (C) BJ5409 yeast cells were transformed with the transcription reporter plasmid YRpβRE(2), co-transformed with either YEpRXRα or pcRB1.4 expression plasmids and YRpβRE(2), or co-transformed with YEpRXRα, pcRB1.4 and YRpβRE(2). The βGal activity present in yeast extracts
was measured as in (A). Values reported are averages of multiple data points and error bars reflect standard deviations, n = 3.
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plated onto minimal media plates containing the βGal
substrate X-GAL (Fig. 1B). Approximately 150,000 transformants were analyzed for the presence of βGal activity
(blue colonies).
Several positive colonies were expanded in solution and
secondarily tested for βGal activity using the βGal substrate ONPG. The βGal enzymatic activity present in yeast
extracts was determined and those cDNA expressing transformants which induced βGal transcription at least 2 fold
over RXR/βRE-βGal yeast were expanded in solution and
extracts were prepared for plasmid rescue by bacterial
transformation [32]. Random bacterial transformants
were used to generate plasmid preps. EcoRI, Hind III
restriction enzyme digests generated a DNA fragment pattern which easily identified pcRB insert containing plasmids separate from RXR expression and βRE-βGal reporter
plasmids also present in every yeast extract.
A pcRB plasmid containing an insert of approximately 1.4
kb in length was isolated (pcRB1.4). To demonstrate the
specific enhancement of RXR mediated transcription versus an enhancement of transcription in general, the
pcRB1.4 plasmid was co-transformed with and without
RXR expression plasmids. In these experiments a reporter
plasmid with two copies of the βRE incorporated into the
βGal reporter plasmid was used to increase the sensitivity
of the assay. RXR transcription was enhanced by pcRB1.4
two fold over RXR expression alone, but pcRB1.4 did not
enhance transcription when co-transformed with the
reporter plasmid alone (Fig. 1C). These results demonstrated that the pcRB1.4 plasmid was autonomously capable of specifically enhancing RXR mediated transcription.
DNA Sequencing Reveals the RXR Transcription
Coregulator to be NPDC-1
The entire pcRB1.4 insert and sub-fragments were subcloned into pBluescript (Stratagene) for DNA sequencing.
A sequence of 1,384 bp was determined. This sequence
was aligned with the Genbank database to screen known
DNA sequences for homology. A very high homology was
displayed between pcRB1.4 and a previously cloned DNA
sequence for the mouse gene NPDC-1 [27]. The pcRB1.4
sequence had only one extended ORF coding for a 331
amino acid protein that displayed a 94% identity with the
mouse protein NPDC-1 (Fig. 2). As with the mouse
sequence, the pcRB1.4 ORF is preceded by a TGA stop
codon two triplets upstream of the ATG translation initiation codon. The pcRB1.4 clone also contains a classical
polyadenylation signal sequence in the same approximate
position as the mouse but ends without a poly-A tail representation. From this information it was concluded that
the pcRB1.4 DNA sequence contains the rat homologue of
the mouse NPDC-1 gene.
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The cDNA for the rNPDC-1 was subsequently used to
screen a human embryonic brain λgt11 cDNA library.
This screen identified a 2.5 kb cDNA that contained an
open reading frame of 325 amino acids and greater than
99% identity with a recently published human homolog
for mNPDC-1 [28].
Figure 2 contains an alignment of rNPDC-1 and hNPDC
with the published sequence for mNPDC-1. The overall
amino acid homology of the NPDC-1 protein between
species suggests that these proteins may have a conserved
function. Some conserved amino acid motifs may be
related to specific function. All three NPDC-1 homologues have a perfectly conserved LXXLL motif (amino
acids 15 – 20, Fig. 2), a sequence that has been shown to
mediate the interaction of coregulatory proteins with
nuclear receptors [22,23].
Northern Analysis of Rat and Human NPDC-1 Tissue
Distribution
The rNPDC-1 cDNA sequence was used as a template for
nick translation synthesis of a radiolabeled DNA probe.
Probe hybridization to a multiple tissue poly-A+ RNA
Northern blot demonstrated the tissue distribution of
rNPDC-1 mRNA (Fig. 3). A single abundant mRNA band
of approximately 1.5 kb was identified in rat brain. This is
consistent with the published expression of NPDC-1
mRNA in mouse brain and suggests that our cloned
sequence represents a majority of the NPDC-1 mRNA
expressed in rat brain [27]. A band of similar intensity was
also present in rat lung. The rat NPDC-1 probe hybridized
with three other mRNA transcripts in the lung of approximately 2.0, 5.0 and 6.3 kb in size. The 1.5 kb and 2.0 kb
bands were also detectable (in order of decreasing intensity) in kidney, skeletal muscle and heart tissues of the rat.
The 1.5 kb and 2.0 kb bands were faintly detectable in the
spleen but there was a relatively stronger representation of
the 6.3 kb band. The 6.3 kb band was also present in the
kidney. The 1.5 kb band was barely detectable in the testis
and not at all in liver.

The human NPDC-1 probe identified two mRNA transcripts of approximately 1.5 and 6.3 kb in size in all tissues examined. These data are similar to those reported by
Qu et. al. [28] and unlike the rat, the relative abundance
of the two transcripts was more consistent in each specific
human tissue. As with NPDC-1 mRNA expression in mice
and rats, human NPDC-1 mRNA was most abundant in
the brain. A considerable amount of NPDC-1 mRNA is
present in the heart and pancreas and to a lesser extent in
placenta, lung, liver, skeletal muscle and kidney. Since the
cloned human cDNA fragment identified here is approximately 2.3 kb in size, has a poly-A tail representation and
a TGA codon immediately upstream of the NPDC-1 ORF,
it is possible that it represents a portion of the 6.3 kb
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1 MATPVPPPSPRHLRL LRLLL SGLILGAALNGATARRPDAT 40
1 MATPVPPPSPRHLRL LRLLL SGLILGAALNGATARRPDAP 40
1 MATPLPPPSPRHLRL LRLLL SGLVLGAALRGAAAGHPDVA 40
****.********** ***** ***.***** **.* .**
41 TCPGSLDCALKRRAKCPPGAHACGPCLQSFQEDQRGFCVP
41 TCPGSLDCALKRRAKCPPGAHACGPCLQSFQEDQRGVCVP
41 ACPGSLDCALKRRARCPPGAHACGPCLQPFQEDQQGLCVP
.*************.************* *****.* ***
81 RKHLSSGEGLPQPRLEEEIDSLAQELALKEKEAGHSRLTA
81 RKHQSSGEGLPQPRLEEEIDSLARELALKEKEAGHPRLTA
81 RMRRPPGGGRPQPRLEDEIDFLAQELARKE--SGHS---T
* .
* * ******.*** **.*** ** .**
.
121 QPLLERAQKLLEPAATLGFSQWGQRLEPGLPSTHGTSSPI
121 QPLPEASQKLLEPAATLGFSQWGQQLEPGLPSTHGTSSPT
116 PPLPKDRQRLPEP-ATLGFSARGQGLELGLPSTPGTPTPT
**
*.* ** ****** ** ** ***** ** .*
161 PHTSLSSRASSGPVQMSPLEPQGRHGNGLTLVLILAFCLA
161 PHTSLSARASSGPVQMSPLEPQGR-GNGLALVLILAFCLA
155 PHTSLGSPVSSDPVHMSPLEPRGGQGDGLALVLILAFCVA
***** . ** **.******.* * **.********.*
201 SSAALAVAALCWCRLQREIRLTQKADYAATAKGPTSPSTP
200 STAALAVAALCWCRLQREIRLTQKADYTATAKGPTSPTTP
195 GAAALSVASLCWCRLQREIRLTQKADY-ATAKAPGSPAAP
.***.**.****************** **** * **..*
241 RISPGDQRLAHSAEMYHYQHQRQQMLCLERHKEPPKELES
240 RISPGDERLAHSAEMYHYQHQRQQMLCLERHKDPPKELES
234 RISPGDQRLAQSAEMYHYQHQRQQMLCLERHKEPPKELDT
******.***.*********************.*****..
281 ASSDEENEDGDFTVYECPGLAPTGEMEVRNPLFDHSTLSA
280 ASSDEENEDGDFTVYECPGLAPTGEMEVRNPLFDHSTLSA
274 ASSDEENEDGDFTVYECPGLAPTGEMEVRNPLFDHAALSA
***********************************..***
321 PVPGPHSLPPLQ 332
320 PVPGPHSSPPLQ 331
314 PLPAPSSPPALP 325
*.* * * * *

80
80
80
120
120
115
160
160
154
200
199
194
240
239
233
280
279
273
320
319
313

Comparative
Figure 2
sequence
alignment of the predicted amino acid sequence of rat and human NPDC-1 with the published mouse amino acid
Comparative alignment of the predicted amino acid sequence of rat and human NPDC-1 with the published
mouse amino acid sequence. The published mouse NPDC-1 amino acid sequence was aligned with cDNA deduced from
rat and human amino acid sequences using the Clustal W(1.4) Multiple Sequence Alignment program (MacVector 7.0.1). An
asterisk, "*" indicates conserved amino acid identity and a period "." indicates amino acid similarity between the three
sequences. A conserved LXXLL motif is indicated by a box.
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Figure 3 analysis of rat and human NPDC-1 tissue distribution
Northern
Northern analysis of rat and human NPDC-1 tissue distribution. Approximately 2 µg of poly A+ RNA from the indicated specific tissues was used to generate rat and human multiple tissues northern blots. Each blot was probed with speciesspecific cDNA derived radiolabeled DNA probes. The location of RNA size markers are indicated.

transcript minus an unusually extended 5' untranslated
region. The 1.5 kb transcript likely represents a splice variant isoform similar in size to the transcript that represents
NPDC-1 expression in mice and rats, although the presence of an alternative, very similar gene transcript that is
detectable with the human NPDC-1 probe cannot be
ruled out.

lected, washed with binding buffer and incubated with Sprotein agarose bound to pull out thioredoxin-S-tagged
NPDC-1. Bound protein was eluted from beads with electrophoresis sample buffer, run on 12.5% SDS-PAGE gels,
Western blotted to nitrocellulose membranes and probed
with specific antisera for the presence of HA-tagged E2F-1
(Fig. 4A), RARβ, or RXRα ••••• 4B).

NPDC-1-RXR and NPDC-1-RAR form Protein-Protein
complexes In Vivo
To test if human NPDC-1 could interact with in vivo
expressed E2F-1, RARβ or RXRα, recombinant Trx-SNPDC-1 was used to pull-down protein from mammalian
cell lysates (Fig. 4). PC12 cells were transfected with
pCMV-HA-E2F-1, pRS-hRARβ, or pRS-hRXRα and incubated for 48 hours. Clarified cell lysates were prepared,
and incubated for 1 hour at 4°C with a 50% slurry of TrxS-NPDC beads. Ligands, atRA and 9cRA were diluted to a
concentration of 1 micromolar into clarified lysate before
the addition of recombinant hNPDC-1. Beads were col-

As seen in Fig. 4A recombinant NPDC was able to pull
down E2F-1 (Fig. 4A), RXRα and RARβ (Fig. 4B) from
PC12 lysates. The interaction with NPDC appeared to be
independent of ligand stimulation. In fact, ligand
appeared to slightly reduce the ability of NPDC to associate with either RXRα or RARβ. As a binding control we
attempted to pull down HA-E2F1 from PC12 lysates. We
demonstrate that human NPDC can bind to E2F1
expressed in mammalian cells. Although a mouse NPDCE2F interaction has been previously demonstrated using
in vitro binding and mammalian transcription protocols
[29,30], these are the first studies demonstrating a
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Figure
RXR,
RAR
4 and E2F-1 proteins form complexes with hNPDC-1 In Vivo
RXR, RAR and E2F-1 proteins form complexes with hNPDC-1 In Vivo PC12 cells were transfected with pCMV-HAE2F-1, pRS-hRARβ, or pRS-hRXRα and incubated for 48 hours. Subsequently clarified cell lysates were prepared, and incubated for with a 50% slurry of Trx-S-hNPDC beads (bacterially expressed hNPDC fused at its carboxyl terminus with S-peptide and thioredoxin tags and affinity purified by binding to S-protein agarose beads as described in the Methods section).
Ligands, atRA and 9cRA were diluted to a concentration of 1 µM into clarified lysate before the addition hNPDC. Beads were
collected, washed, bound protein was eluted from beads with 2X SDS electrophoresis sample buffer and proteins were separated on 12.5% SDS-PAGE gels. Proteins were transferred to nitrocellulose membranes and probed for the presence of HAtagged E2F-1, RARβ, or RXRα••••••••••••••
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potential for in vivo complex formation between hNPDC1 and E2F proteins.
NPDC-1 can bind directly to RXR and RXR/RAR
complexes
To characterize NPDC-1 and RXR interactions, a bacterial
extract of Flag-tagged rNPDC was incubated, in the presence of 9cRA or bacterially expressed hRARβ, with GSTRXR immobilized on glutathione agarose beads. After
extensive washing, bound proteins were eluted from the
GST-RXR beads, electrophoresed and analyzed by Western
blot probing with an anti-flag M2 monoclonal antibody
(Fig. 5). This assay demonstrated that agarose bound GSTRXR was able to specifically pull down a protein of the
expected size for recombinant rNPDC (F), not found
when control agarose bound GST beads were used. These
results demonstrate that bacterially expressed hRXRα
recombinant protein, in the absence or presence of a
homodimer inducing ligand, or in the presence of a
hRARβ heterodimer partner, was capable of interacting
with NPDC-1.
NPDC-1 Facilitates the In Vitro DNA Binding of RXR
Homodimers and RAR/RXR Heterodimers
Ligand induced RXR homodimers and RAR/RXR heterodimers will form in solution and are capable of binding to specific HRE DNA sequences [33–35]. To
investigate the impact NPDC-1 has on nuclear receptor
DNA binding, recombinant human NPDC-1 was analyzed for its ability to modulate gel mobility shift complexes generated using PC12 cell nuclear extracts and a
radiolabeled DR-5 βRARE DNA response element (Fig.
6A). The βRARE generated two major shift complexes in
the presence of PC12 extracts. The addition of recombinant hNPDC was observed to substantially enhance the
formation of the lower shift complex at the expense of the
higher shift complex. NPDC-1 did not form a measurable
unique complex with the radiolabeled DNA. Curiously,
the enhanced protein:DNA complex formed without a
significant change in mobility indicating that NPDC-1
facilitates DNA binding without remaining in strong association with either proteins or DNA.

To measure the direct effect of NPDC-1 on the DNA binding properties of retinoic receptors, RXR and NPDC-1 bacterially expressed protein was tested for binding on a DR1 RXRE probe (Fig. 6B). As we, and others, have previously observed, RXR bound to the DR-1 probe in the
absence of ligand, forming, what appears to be, a
homodimer complex (upper band) and a monomer complex (lower band). The addition of NPDC-1 increased
both the upper and lower complexes, again without any
observable increase in complex mobility. To evaluate the
presence or absence of NPDC-1 in these complexes, supershifts were performed with antibodies for RXRα and
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NPDC-1 (Fig. 6C). Supershift experiments demonstrated
that NPDC-1 is not part of the RXR/DR-1 complex and
that RXRα is a major component of both lower and upper
bands.
hNPDC-1 represses E2F-1 mediated transcription
As demonstrated above and similar to previous reports for
mouse NPDC-1 [29,30], human NPDC-1 preferentially
binds E2F-1. To determine the functional effect of human
NPDC-1 expression on E2F mediated transcription, the
E2F response element (E2FRE) found in the promoter
region of the dihydrofolate reductase gene was sub-cloned
into a transcriptional reporter plasmid [36]. Multiple
members of the E2F family of transcription factors have
been shown to activate transcription via this type of
response element. Transient transfection of the E2FRE
reporter plasmid into the human hepatocellular carcinoma cell line HepG2 resulted in a constitutive level of
transcriptional activity that was inhibited 65% by the cotransfection of the human NPDC-1 expression plasmid
(Fig. 7A). These data with hNPDC-1 are in line with those
reported for mNPDC-1 and support a role for this protein
in the regulation of molecular events mediated by the
human E2F family of transcription factors.
NPDC-1 Functions in Mammalian Cell Transcription
Assays
To examine NPDC-1 effects on nuclear receptor mediated
transcriptional activation in mammalian cells, the rat
NPDC-1 gene was sub-cloned into a cytomegalovirus
(CMV) promoter driven mammalian expression plasmid.
Transfections of mammalian expression constructs for
steroid/nuclear receptor family members hRXRα, hRARβ,
rat peroxisome proliferator-activated receptor alpha
(rPPARα), human estrogen receptor alpha (ERα) and
human vitamin D receptor (hVDR), along with their
respective luciferase reporter constructs were analyzed
with respect to hNPDC effects on ligand-induced transcriptional activation mediated by these receptors (Fig.
7B). As seen in Figure 7B, NPDC-1 strongly repressed transcription mediated by the retinoid receptors, moderately
repressed transcription mediated by PPARα and ERα, and
had very little effect on VDR.
NPDC-1 Transcriptional Repression Appears Not to be
Through its LXXLL Motif
The above data suggest NPDC-1 functions as a steroid/
hormone nuclear receptor corepressor protein [17–21].
Many of the corepressors identified thus far have been
shown to mediate their activities through specific interactions between receptors and a short conserved LXXLL
amino acid sequence motif found on the repressor
proteins [22,23]. Within the amino terminus of the NPDC
protein there exists a highly conserved LLRLLL motif (see
Fig. 2). To analyze the functional role of this LLRLLL motif
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Figureprotein-protein
Direct
5
interactions between NPDC-1 and RXR
Direct protein-protein interactions between NPDC-1 and RXR. Bacterially expressed flag epitope tagged NPDC-1
[NPDC(F)] (40 µg) was incubated with glutathione-agarose bound GST/human RXRα (GST-RXR) fusion protein in the absence
or presence of bacterially expressed human RARγ (RAR) (60 µg) or in the presence of 9-cis retinoic acid (9cRA) (10-6 M) as
indicated. NPDC(F) was also incubated with glutathione-agarose bound GST. After extensive washing, the retained proteins
were resolved by gel electrophoresis and analyzed by immunoblot with anti-flag M2 antibodies. One percent (0.4 µg) of the
available NPDC(F) input was also electrophoresed and a unique immunoreactive band of approximately 45 kDa representing
NPDC(F) is indicated by an arrow. The position of prestained molecular weight standards are shown.

in transcriptional repression mediated by NPDC-1, a
series of mutations in the LLRLLL motif were made that

sequentially converted key leucines into alanines. These
mutated NPDC-1 constructs were analyzed in the mam-
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Figure
NPDC-16Alters RARβ••••α and RXRα DNA binding properties
NPDC-1 Alters RARβ••••α and RXRα DNA binding properties. Oligonucleotides corresponding to the consensus
RARβ•RARE (DR-5: A) or the consensus RXRα RARE (DR-1: B & C) were end-labeled with 32-P by T4 polynucleotide kinase
according to the manufacture's instructions. The resultant DNA binding probes were incubated with PC12 lysate (A), recombinant NPDC-1 and recombinant RXRα (B & C) as indicated. DNA:protein complexes were resolved on non-denaturing PAGE
gels which were subsequently exposed to Kodak Xar-5 film. In C, the presence of NPDC-1 within the RXR gel-shift complex
was assayed by supershift. Antibodies specific for either NPDC-1 or RXR were used to identify proteins present in the
complex.

malian transcription assay for their ability to repress RARmediated transcription (Fig. 8). As seen here, none of the
mutations were able to impact the repression associated
with NPDC-1 cotransfection. These data suggest the
LXXLL motifs of NPDC-1 do not play a key role in its ability to repress transcription.
RXR Binds the Amino Terminus of NPDC-1
In the above studies we were able to demonstrate binding
of NPDC-1 to retinoid receptors, but the transcription
studies suggest this may not be through its LXXLL motifs.
To localize NDPC-1 binding to RXR, a series of deletion
constructs were made sequentially deleting sequence
information from the amino and carboxyl termini of
hNPDC-1 (Fig. 9A). These deletion constructs were used
to generate recombinant hNPDC-1 protein and were analyzed in standard pull-down assays for their ability to
interact with recombinant hRXRα protein (Fig. 9B). As
seen in Fig. 9B, deletion of a region between amino acids
76 and 112 substantially reduces NPDC-1 interactions,
suggesting the putative coil-coil domain residing in this
region may play an important role in NPDC-1 interactions with RXRα.

Discussion
In this study, the gene for the rat homologue of the mouse
NPDC-1 protein was identified as a positively regulator of
RXR mediated transcriptional activation in yeast. The
cloning approach used took advantage of RXR's inherent
ability to bind DNA and activate transcription in yeast. By
creating the proper conditions for the sensitive detection
of minimal transcriptional enhancement, random rat
brain cDNA products were screened for their ability to
facilitate RXR function. Whereas the yeast two-hybrid system has most often been used to identify a positive protein-protein interaction between cDNA products and the
ligand binding domain of nuclear receptors [37–43], the
strategy used here screens for a functional relationship
between cDNA products and the entire receptor, without
the addition of hybrid domains. A rat NPDC-1 expression
plasmid autonomously affected transcription of a yeast
reporter plasmid when co-expressed with RXR but had no
enhancing activity when transformed alone.
The rat NPDC-1 gene sequence was subsequently used to
screen a human brain cDNA library from which a human
NPDC-1 homologue was identified. Alignment of the
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Figure 7selectively represses nuclear receptor-mediated transcription
NPDC-1
NPDC-1 selectively represses nuclear receptor-mediated transcription. A. rNPDC-1 was analyzed for its ability to
modulate the transcription mediated by endogenous E2F transcription factors. A pBL-E2FRE-tk-luc (E2FRE) reporter plasmid
and a mammalian expression β-galactosidase construct were transfected into HepG2 cells with and without a mammalian
expression construct for rNPDC-1. Luciferase data was normalized as described above and data was reported as a % of the
constitutive activation of the E2F reporter plasmid. B. Mammalian expression plasmids for pRS-hRXRα, pRS-hRARβ, pRSrPPARα, pRS-hERα and pRS-hVDR were transiently transfected into HEK 293 cells along with their respective luciferase
reporter constructs {hRXRα: pBL-CRBP2, hRARβ: pBL-βRE(2), rPPARα: pBL-AOXRE, hERα: pBL-ERE, and hVDR: pBLVDRE(3)} and with or without a mammalian expression construct for rNPDC-1. Transfected cells were incubated with appropriate ligands at indicated doses. A mammalian expression β-galactosidase construct was included in all transfections to normalize for transfection efficiency. Multiple data points were collected and calculated as average induced luciferase activity
normalized to constitutive βGal activity {normalized response = average full integral luciferase activity/ [average (βGal activity/
min)]}. Data is expressed here as a percentage of the normalized response for the ligand induced receptor-reporter constructs. Error bars represent the value of standard deviations n = 4.
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NPDC-1
pression
LXXLL
RAR-mediated
Motifs aretranscription
not implicated in NPDC-1 coreNPDC-1 LXXLL Motifs are not implicated in NPDC1 corepression of RAR-mediated transcription Site
directed mutagenesis was used to change critical leucines in
the pCMV-hNPDC-1 LLRLLL motif (see insert in figure for
specifics) to alanines. These expression constructs were
cotransfected with the RAR/RXR-specific βRE reporter construct into human embryonic kidney cells (HEK) and analyzed
for transcriptional activation of the reporter in the presence
of 10-6 M all trans retinoic acid (atRA). Transfections were
normalized to a β-galactosidase expression construct
included in all transfections, and data was calculated as
described in Fig. 7. Data was expressed as a percent of the
reporter alone transfection and statistics were performed on
the results of 3 independent experiments. Error bars represent the value of standard deviations n = 3.

mouse NPDC-1 amino acid sequence with the rat and
human proteins demonstrated that these proteins are
evolutionarily well conserved, indicating that they likely
perform a similar and essential function. An LXXLL amino
acid motif found in a number of transcription coregulators has been shown to be necessary and sufficient to
mediate the binding of coregulators to liganded nuclear
receptors [22,23]. X-ray crystal structure analysis suggest
the mechanism for the interaction of nuclear receptors
with coregulators involves specific contacts between a
coregulators LXXLL motif and a highly conserved nuclear
receptors motif, termed activating function-2 (AF-2),
located at the C terminus of nuclear receptors [44,45]. The
three species specific NPDC-1 proteins have a conserved
LXXLL amino acid sequence proximal to their amino
terminus, but mutation studies presented here suggest this

domain does not play an integral role in the repression of
transcription mediated by NPDC-1. Furthermore the deletion studies presented here suggest that the NPDC more
probably interacts with RXR through an area localized
more centrally in the protein. The most obvious protein
interaction domain in this region is a coil-coil domain
located between amino acids 76–112 [30]. Finally, this
observation is not unprecedented in that PNRC, a recently
identified nuclear receptor coregulatory protein [46,47],
has also been observed to bind nuclear receptors through
a motif other than its LXXLL motif. Further studies are
ongoing to establish the role of both the NPDC-1 LXXLL
motif and coil-coil domain and their functional significance in the coregulation of retinoid receptor-mediated
transcription events.
Northern analysis and reverse transcriptase-PCR amplification of RNA showed that the mouse NPDC-1 was preferentially expressed in the nervous system and not
detectable in the other tissues examined [27]. In contrast,
Northern analysis revealed that human and rat NPDC-1
mRNA is variably, but much more ubiquitously
expressed. Similar to previously published data [28], our
results suggest that NPDC-1 mRNA in humans exists as
multiple splice variant isoforms. The cloned human
cDNA isolated was larger than the predominant smaller
mRNA species seen in every tissue, indicating that it likely
represents a sub-fragment of the larger transcript,
although we cannot rule out the existence of a unique
homologous mRNA species. In rats we identified a single
but abundant brain mRNA species. Its size approximates
that found in mouse brain tissue [27] and would be
largely represented by our cloned cDNA. Some of the
other tissues probed displayed an mRNA species of a similar size along with the variable presence of larger hybridizing transcripts. The tissue specific relative intensities of
these larger hybridizing transcripts were not consistent,
which confuses their interpretation. Further examination
will be required to identify them as splice variant isoforms
or as cross hybridizing unique gene products.
Of special note was the seemingly opportunistic cloning
of this RXR coregulator in a ligand independent yeast
assay. Efficient DNA binding normally requires the ligand
dependent homodimerization of RXR [35]. Although RXR
mediates significant ligand inducible transcriptional
response in yeast, unliganded RXR induces minimal activation from a βRE containing reporter plasmid. RXR has a
higher binding affinity for a response element from the
cellular retinoic acid binding protein, type II (CRBPII)
promoter region [48]. A significant amount of constitutive
activity results from a CRBPII response element containing yeast reporter plasmid and unliganded RXR [26], indicating that unliganded RXR is capable of facilitating
transcription in yeast and a limiting condition for this
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Figure
RXR
binds
9 the amino terminus of hNPDC-1
RXR binds the amino terminus of hNPDC-1. Approximately 10 µg of recombinant S-tagged hNPDC-1 or NPDC-1 deletion mutant (A) was pre-coupled to S-protein to generate a 50% slurry of NPDC-1-beads. Reactions containing 30 µl NPDCbeads, 5 µg of recombinant GST-RXRα and 300 µl of 1X gel-shift buffer were incubated at 4°C for 1 hour with rotation. S-protein pellets were collected by centrifugation and washed 3 times in gel-shift buffer. Proteins were released from the pellet by
resuspending S-protein agarose in 2X SDS-PAGE sample buffer. The amount of GST-RXRα bound to beads was analyzed by
Western blotting onto nitrocellulose filters and probing blots with anti-RXRα (B, top panel). To normalize for unequal expression of the various deletion mutants, duplicate reactions without GST-RXRα were performed and subjected to coomassie
staining instead of immunoblotting, and NIH Image Software was used to normalize the bands in the immunoblot (B, top panel)
to the amount of S-tagged NPDC-1 precipitated in the coomassie stained gel. Normalized binding is depicted in B, bottom
panel.
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function may be RXR's ability to bind DNA. From this perspective, it seems likely that the procedure by which we
cloned the rat NPDC-1 gene would identify gene products
that influence RXR's ability to bind DNA. The gel mobility
shift assay results support the contention that NPDC-1
can facilitate the binding of DNA by unliganded RAR/RXR
heterodimers or RXR homodimers. Although difficult to
establish, there is precedent for an enhancement of DNA
binding as a mechanism for nuclear receptor coregulator
function. Human homologues of the S. cerevisiae SWI/
SNF family of genes have been shown to function as
coregulators of transcriptional activation by nuclear
receptors, including RAR [49,50]. These coregulators have
been characterized to function as members of large multisubunit complexes that alter chromatin structure to facilitate receptor DNA binding. Human homologues of the S.
cerevisiae SWI/SNF gene products exhibit a protein-protein interaction with the nuclear receptor AF-2 domain
and potentially require the receptor's DNA binding ability
to associate with specific promoter regions for function
[51]. The yeast SWI/SNF complex stimulates the binding
of DNA by the yeast transcription factor GAL4 in GMSAs
without maintaining a strong association with the protein/DNA complex [52], similar to what is observed here
with NPDC-1.
We show that NPDC-1 can repress the induction of transcription in mammalian cells by several nuclear/steroid
receptor family members. This activity places NPDC-1
into an expanding list of proteins and RNAs whose structure appear to be targeted to DNA by transcription factors
and whose function appears to be integrated into regulation of transcription by the RNA polymerase complex
[53–57]. Data demonstrating that NPDC-1 can directly
interact with nuclear receptors, can influence nuclear
receptor binding to DNA and can bind to and repress E2F
mediated transcription events [30] would strongly suggest
NPDC-1 is a true corepressor protein. There also appears
to be some specificity in NPDC-1's ability to corepress
transcription, with very strong corepression occurring
with RXR and the RXR heterodimer partner RAR, only
moderate transcriptional repression with the RXR heterodimer partner PPAR and the homodimerizing receptor
ER, and little if any effects on transcription mediated by
the RXR heterodimerizing receptor VDR. However, RXR's
promiscuous nature as a heterodimer partner with a
number of other receptors implies that NPDC-1 co-regulation of transcription may be dramatic and its expression
involved with sweeping changes in the transcriptional regulation of genes within a cell. The up-regulation of mouse
NPDC-1 expression has been intimately linked in vivo
with a variety of morphological changes as precursor
nerve cells begin to terminally differentiate and this
expression is maintained up to the adult age [29]. P19
cells are a pluripotent murine embryonic carcinoma cell
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line that can be induced by atRA to differentiate into cells
that are biochemically and morphologically similar to
cells of the central nervous system [58]. It has been shown
that atRA induced differentiation of P19 cells results in the
expression of mNPDC-1 [29]. Whether NPDC-1 expression is directly regulated by an atRA activated RAR or is
under the control of some other differentiation induced
transcriptional regulator remains to be examined. However, atRA up-regulation of a negative mediator of its own
signal would be somewhat inconsistent with this ligand's
signaling pathway which is also known to up-regulate the
expression of the RARα and RARβ genes [59].
As has been shown for mNPDC-1 [29,30] hNPDC-1 was
observed to directly interact with and suppress transcription mediated by E2F-1. E2F trans-activation of transcription is critical for the regulated G1 to S phase transition of
the cell cycle [15]. The subsequent down regulation of E2F
activity during S phase is also critical for viable cell propagation and is believed to be largely the result of its association with Rb or Rb related proteins [16]. It has been
shown that the Rb-E2F complex will bind DNA but function to inhibit E2F-responsive genes. NPDC-1 may inhibit
overall E2F transcription by preferentially promoting the
binding of the inhibitory complex to DNA over the binding of the activating E2F complex. In the absence of
ligand, RAR/RXR heterodimers have been theorized to
associate with transcription repressing co-regulators
[42,60]. NPDC-1 association with RXR is ligand and RAR
heterodimer independent implying that NPDC-1 may
also contribute to the repression of RAR responsive genes
in the absence of atRA. The E2F-1 factor is thought to play
a critical role in the maintenance of cellular proliferation
whereas atRA-treated cells normally proliferate at reduced
rates. There are some reports suggesting that some intermediate mechanism links these apparently antagonistic
pathways [13,61]. Limited availability of NPDC-1 may be
involved in the competitive relationship between these
transcription factors' function.

Conclusions
The evidence presented here demonstrates that NPDC-1
has remained highly conserved through human and
rodent evolution and is capable of binding retinoid receptors, influencing their associations with DNA binding and
repressing their ability to regulate gene expression. These
results, along with previously published data demonstrating mNPDC-1' s ability to repress proliferation and
stimulate differentiation, suggest that NPDC-1 plays an
important role in retinoid signaling as cells differentiate.
Cumulatively these data categorize NPDC-1 as a tissuespecific corepressor of retinoid-mediated transcription
directly linked to differentiation of neuronal cells.
Although NPDC-1 has yet to be aligned with any specific
neuronal tumorigenesis event it's intrinsic role in
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proliferation and differentiation suggest it might function
as a tumor suppressor gene. Further studies will be necessary to establish this possibility

Materials and methods
Plasmids and Constructions
The yeast expression plasmids YEphRXRα(TRP),
YEphRARγ(LEU) and the yeast transcription reporter plasmids YRpβRE(1) and YRpβRE(2) have been described
elsewhere [26]. The mammalian expression plasmid
pCMVβ (Clontech) was modified to introduce a bacterial
T7 promoter enabling overlapping expression from this
promoter and the CMV immediate early gene promoter/
enhancer. A polycloning site was also introduced downstream from these promoters, replacing the β-galactosidase (βGal) gene, and the resulting plasmid was
designated pCMV/T7PC. NotI fragments containing the
cloned rat and human NPDC-1 genes were sub-cloned
into pCMV/T7PC creating pCMVrNPDC-1. The mammalian expression plasmids pRShRARβ•[26], pRShRXRα•
[26], pRShERα [62], pRSrPPARα•[25], pRShVDR [63]
and pRSβGal [62] are described elsewhere. The mammalian reporter plasmids βRE-tk-luc and E2FRE-tk-luc were
constructed by sub-cloning a single copy of annealed synthetic oligonucleotides into HindIII or SalI – BamHI,
respectively, prepared pBL-tk-luc vector [62]. The
sequence of the oligonucleotides used were as follows:
βRE, 5'-AGCTTAAGGGTTCACCGAAAGTTCACTCGCAT-3'
and 3'-ATTCCCAAGTGGCTTTCAAGTGAGCGTATCGA5'; E2FRE, 5'-TCGACATGCAATTTCGCGCCAAACTTGGGA-3' and 3'-GTACGTTAAAGCGCGGTTTGAACCCTCTAG-5'. The mammalian reporter plasmid ERE(5)-MTVluc was constructed by sub-cloning five copies of annealed
synthetic oligonucleotides (5'-AGCTGTCAGGTCACAGTGACCTGAT-3' and 3'-CAGTCCAGTGTCACTGGACTATCGA-5') into HindIII prepared MTV-luc [64].

Single amino acid mutations in the LLRLLL motif of the
pCMV-hNPDC-1 cDNA were made using the
QuikChange Site Directed Mutagenesis Kit (Stratagene)
and protocols as described in the users manual. Oligonucleotides used in the construction of the various mutations include M1-ALRLLL
(5'-CGCGGCACCTGCGGgcGCTGCGGCTGCTGCTCTCCGGCCTCGTCC-3' and
5'GGACGAGGCCGGAGAGCAGCAGCCGCAGCGCCCGC
AGGTGCCGCG-3'), M2-LLRLAL (5'-CGCGGCACCTGCGGCTGCTGCGGCTGgcGCTCTCCGGCCTCGTCC-3' and
5'-GGACGAGGCCGGAGAGCGCCAGCCGCAGCGCCCGCAGGTGCCGCG-3') and M3-AARLLL
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5'-CGCGGCACCTGCGGgcGgcGCGGCTGCTGCTCTCCGGCCTCGTCC-3' and
5'-GGACGAGGCCGGAGAGCAGCAGCCGCGCCGCCCGCAGGTGCCGCG-3'). The integrity of introduced mutations was verified by DNA sequencing.
A bacterial expression construct for full-length hNPDC-1
and a series of hNPDC-1 mutant constructs were generated in pET-32a (Novagen). Synthetic oligonucleotide
primers for full-length hNPDC-1 (forward: 5'-TTGAATTCATGGCGACGCCGCTGC-3' and reverse: 5'-TTGGATCCAGTGGCAGTGCAGGCGGTG-3'), a D1 mutant
containing amino acids 1–268 (forward: 5'-TTGAATTCATGGCGACGCCGCTGC-3' and reverse: 5'-TTGGATCCATGGGTGGCTCTTTATGC-3'), a D2 mutant truncating
the predicted transmembrane domain of hNPDC-1 and
containing amino acids 1–182 (forward: 5'-TGAATTCATGGCGACGCCGCTGC-3' and reverse: 5'-TTGGATCCATGCCGTCGCCTTGCCCTC-3'), a D3 mutant truncating
NPDC-1 just before the putative coil-coil domain and
containing amino acids 1–76 (forward: 5'-TTGAATTCATGGCGACGCCGCTGC-3' and reverse: 5'-TTGGATCCATCCCTTGCTGGTCCTCC-3'), a D4 mutant retaining the
putative transmembrane domain but deleting the LXXLL
motif and containing residues 112–325 (forward: 5'TTGAATTCGGACACTCAACTCCGC-3') and reverse: 5'TTGGATCCAGTGGCAGTGCAGGCGGTG-3') and a D5
mutant retaining all residues after the putative transmembrane domain and containing residues 205–325 (forward: 5'-TTGAATTCTGCTGGTGCAGGCTGCAG-3' and
reverse: 5'-TTGGATCCAGTGGCAGTGCAGGCGGTG-3')
were used in polymerase chain reaction technology (PCR)
reactions to generate a full-length hNPDC-1 and mutant
fragments containing terminal EcoRI (5') and BamHI (3')
restriction sites. Subsequently the hNPDC-1 and hNPDC1 mutant PCR fragments were subcloned into EcoRI/
BamHI restricted pET32-a vector. These constructs generated hNPDC-1 proteins tagged with thioredoxin (TRX),
6xHis, and S-protein at its amino terminus. The integrity
of all plasmid constructs and the composition of unique
cloned cDNAs were confirmed by dideoxy sequencing.
Yeast Expression Library Screening and Transcription
Assay
Reconstitution of RXR transcriptional activation in the
auxotrophic mutant S. cerevisiae cell line BJ5409 (MAT•,
leu2D, his3D200, ura3–52, tr1) has been described elsewhere [26]. An established YEpRXRα (TRP), YRpβRE(1)
transformant was further transformed with a rat brain
cDNA yeast expression library [31], a generous gift of Dr.
Robert Dickson, University of Kentucky, by the method of
lithium acetate [65]. Transformed yeast were plated onto
yeast nitrogen base, 2% bacto agar plates supplemented
with 2% glucose, 20 µg/ml adenine sulfate, 20 µg/ml his-
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tidine-HCl, 10 µM CuSO4, 0.5 µM all-trans retinoic acid
and 0.06 mg/ml 5-bromo-4-chloro-3-indolyl-β-o-galactopyranoside (X-GAL). Activation of βGal transcription by
yeast grown in solution was determined as previously
described [26] with the following modifications. The βGal
enzymatic activity present in yeast extracts after 22–24 hr
incubation in minimal media plus 25 µM CuSO4 was
determined by measuring the conversion of the o-nitrophenyl-β-D-galactopyranoside (ONPG) colorimetric substrate (A415) normalized to cell number approximations
(A600). Yeast ONPG transcription assays were repeated at
least twice with separate transformants and yielded similar results.
Cloning human NPDC-1
A full-length cDNA fragment for rNPDC-1 was labeled
with 32P by nick translation and used to screen a λgt-11
human fetal brain cDNA library (Clontech) [66]. Utilizing
dideoxy DNA sequencing techniques, a 2.5 kb insert containing λgt-11 clone was established to harbor the complete coding sequence for the human homolog of
mNPDC-1 [28].
Northern Blot Analysis
Rat and human Multiple Tissue Northern (MTN) blots
were purchased from Clontech Laboratories Inc. The rat
and human cDNA clones were used to prepare [α-32P]labeled DNA probes by nick translation of doublestranded fragments [66]. The blots were probed using
ExpressHyb solution as suggested by the manufacturer
(Clontech).
Bacterial Protein Expression
Bacterially expressed NPDC-1 (Trx-S-NPDC) was purified
from BL21-CodonPlus-RP E. coli (Stratagene) harboring
the pET32a-hNPDC-1 expression construct. An overnight
culture was diluted 1:5 into 2xYT bacterial media and
incubated at 37°C for 2 hours. Subsequently, cells were
moved to room temperature, grown to 0.6 OD600 and
induced with 1 mM IPTG for an additional 4 hours. Cells
were collected at 6000 × g for 10 minutes. The pellet was
resuspended in 20 ml triple detergent lysis buffer (50 mM
Tris-8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, and 0.5%
sodium deoxycholate) supplemented with 1 mg/ml lysozyme, protease inhibitors (Roche) and Benzonase nuclease (Novagen). Cells were allowed to lyse for 20 minutes
at room temperature. Lysate was clarified in 50 ml
Oakridge tubes at 25,000 × g for 20 minutes. Clarified
lysate was injected onto HiTrap chelating HP columns
(Amersham Pharmacia) preloaded with nickel. Bound
protein was washed with 10 column volumes of His-wash
(50 mM Tris-8.0, 500 mM NaCl, and 20 mM Imidazole).
Proteins were eluted in His-elution buffer (50 mM Tris8.0, 500 mM NaCl, and 500 mM Imidazole) and subsequently desalted on a HiTrap desalting column (Amer-
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sham Pharmacia) into TBS-P (10 mM Tris-7.6, 150 mM
NaCl, and 10% glycerol).
Bacterially expressed pGEX-hRXRα was purified using
standard GST-purification techniques except as modified
below. Cells were collected and clarified lysates were produced as above. Lysates were injected onto a GST-rap HP
column (Amersham Pharmacia) and washed with 10 column volumes of TBS-P. Proteins were eluted with 25 mM
glutathione pH 7.0 and desalted into TBS-P.
Gel Mobility Shift Assay
Gel mobility shift assays were performed essentially as
described previously [11]. Briefly, annealed synthetic oligonucleotides coding for the DR-5 RARE (5'-AGCTTCAGGTCAGAAGGTCAGAGAGCT-3') and DR-1 RARE (5'TCGAGGGTAGGGTTCACCGAAAGTTCACTCG-3') were
radioactively end-labeled with [γ-32P]-ATP using T4 polynucleotide kinase (PNK) [66]. Labeled probes were incubated with variable combinations of recombinant protein
or PC12 nuclear extract in a 20 ul reaction mixture (5 mM
Tris pH 7.9, 15 mM HEPES-KOH pH 7.9, 5 mM EDTA, 3.5
mM MgCl2, 5 mM DTT, 0.1% Tween-20, 10% Glycerol,
50 mM KCl) as follows: NPDC (10 µg) and RXR (5 µg)
plus PC12 (25 µg). The protein/DNA complexes were separated from free radiolabeled DNA by electrophoresis in
non-denaturing polyacrylamide gels and autoradiographed. In order to identify proteins present in complexes, supershifts with antibodies to RXRα (D-20, Santa
Cruz) and NPDC-1 (custom antibody and α-thioredoxin,
Thio-probe, Santa Cruz) were used with the above
reactions.
In Vivo Pull-downs
The ability of NPDC to interact with in vivo expressed
RARβ and RXRα was assayed by using Trx-S-NPDC as a
pull-down reagent. PC12 cells were transfected with either
pCMV-RARβ or pCMV-RXRα using Effectene reagent
(Qiagen). After 48 hours cells were lysed on the plate in
200 µL of lysis buffer-PD (50 mM Tris-7.5, 150 mM NaCl,
20 mM MgCl2, 10% glycerol, 1% NP-40) supplemented
with 1X protease inhibitors (Calbiochem).

Trx-S-NPDC was prebound to S-protein covalently
attached to agarose beads for 20 minutes. 30 µL of a 50%
slurry of beads was added to 300 µL of buffer PD. 100 µg
of cell lysate expressing HA-E2F-1, RARβ, or RXRα were
added to the tubes and incubated with rotation for 1 hour
at 4°C. Beads were collected and washed three times in
buffer PD. Bound-proteins were eluted by adding 20 µL of
2X SDS-PAGE sample buffer. Samples were run on a
12.5% SDS-Page gel and immunoblotted onto nitrocellulose filters. Filters were probed with anti-HA (Cell
Signaling), anti-RARβ (C-19, Santa Cruz), or anti-RXRα
(D-20, Santa Cruz).
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In Vitro Pull-Down Assays
Agarose-glutathione (Ag-G) bound Glutathione-S-Transferase (GST) and GST-RXR fusion protein were prepared
from BL21 (DE3) LysS cell transformants as described
above, with the exception that agarose bound recombinant protein was not eluted but rather stored bound to
beads.
Bacterial
extracts
containing
pETCFlag,
pETrNPDC(F) and pEThRARγ were generated as described
above with the exception that cleared soluble fractions
were used or stored at -70°C without further affinity purification. Protein concentrations were determined using
Bio-Rad Protein Assay per the manufacturer's instructions
(Bio-Rad).

The pull-down assays were performed as described previously [67]. Briefly, 30 µl of a GST-RXR agarose bound
33% protein slurry was pre-equilibrated with NENT buffer
(20 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5%
Nonidet P-40) and incubated for 60 min at room temperature with 40 µg of pETrNPDC(F) extracts without and/or
with 60 µg of pEThRARγ extracts or 1 µM 9-cis retinoic
acid. Successive washes with NENT removed unbound
material and bound material was eluted from Ag-G by
incubation in electrophoresis sample buffer. Eluted proteins were Western blotted onto nitrocellulose filters and
probed with an anti-Flag M2 monoclonal antibody
(Sigma) at 30 µg/ml. Immunoreactive bands were
detected by autoradiography on X-ray film. MultiMark
pre-stained, multi-colored proteins (NOVEX) were used
to assess protein transfer and as molecular weight
standards.
Mammalian Cell Transcription Assay
Transient transfections were conducted with either the
human embryonal kidney cell line 293, or the human
hepatocellular carcinoma cell line, HepG2. The cells were
transiently transfected by the method of calcium
phosphate as previously described [68]. Following a 6 hr
incubation with transfecting plasmids in 10 cm plates,
cells were replated into 96 well plates, plus or minus activating ligands. After 42–48 hours, induced luciferase and
normalizing βGal activities were determined as previously
described [69]. The amount of plasmid used per 10 cm
plate transfection was as follows: βRE-tk-luc, 2 µg; ERE(5)MTV-luc, 4 µg; E2FRE-tk-luc, 5 µg; pRShER, 1 µg; pCMVrNPDC-1 or pCMVhNPDC-1, 4 µg in βRE and E2FRE
experiments and 2 µg in ERE experiments; pRSβGal, 4 µg
in βRE and ERE experiments and 5 µg in E2FRE experiments. The total amount of plasmid per 10 cm plate transient transfection was brought to 20 µg with pUC19 DNA.

Abbreviations
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HRE, hormone response element; βRE, RAR beta response
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element; DR(n), direct repeat of the hormone response
element consensus sequence separated by "n" basepairs;
NPDC-1, neural proliferation differentiation and control
protein one; Rb, retinoblastoma; ORF, open reading
frame; βGal, beta-galactosidase; pcRB, plasmid expressing
rat brain cDNA; ONPG, o-nitrophenyl-β-D-galactopyranoside; X-GAL, 5-bromo-4-chloro-3-indolyl-β-o-galactopyranoside; CMV, cytomegalovirus; GST, glutathione-Stransferase; Ag-G, agarose bound glutathione; GMSA, gel
mobility shift assay; ERα, estrogen receptor alpha; ERE,
estrogen receptor response element; E2FRE, E2F response
element; E2, beta estradiol; AF-2, activating function-2;
CRBPII, cellular retinoic acid binding protein, type II;
MTN, multiple tissue Northern.
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